Wegener's granulomatosis and microscopic polyangiitis are ANCA-associated vasculitides with significant morbidity and mortality. The long-term survival of patients with ANCA-associated vasculitis treated with current regimens is uncertain.
INTRODUCTION
Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA) are primary vasculitides of unknown cause characterized by necrotizing inflammation involving predominantly small blood vessels, and the presence of circulating antineutrophil cytoplasmic antibodies (ANCA) in the majority of patients at diagnosis. they are often grouped as "ANCA-associated vasculitis" because of striking similarities in histology, absence of immune deposits, response to therapy and the likely contribution of ANCA to the pathogenesis.
The introduction of immunosuppression with cyclophosphamide and corticosteroids in the 1960's led to a dramatic improvement in prognosis with over 90% of patients achieving remission compared to a mortality of 80% at one year in untreated patients.
1;2 the addition of plasma exchange to immunosuppression showed promise in improving renal recovery in early small studies. 3 However, these advances were achieved at the cost of treatment-related toxicity such as hemorrhagic cystitis, bladder cancer, lymphoproliferative disease, myelodysplasia and infertility due to the cumulative exposure to cyclophosphamide.
4;5
the European Vasculitis Study Group (EUVAS) standardized disease definitions, diagnostic criteria and disease assessment, and defined four disease stages according to severity and extent at presentation. 6 Four randomized controlled trials were launched to study treatment regimens tailored to different disease stages in newly diagnosed patients with ANCA-associated vasculitis. [7] [8] [9] [10] Despite advances in the treatment of ANCA-associated vasculitis, retrospective studies limited to patients with Wegener's granulomatosis suggest that there still is an excess mortality compared to the general population.
11;12
This study aimed to describe the long-term patient survival and possible prognostic factors at presentation in an international, multicenter, prospectively recruited representative patient cohort, who were treated according to strictly defined protocols at presentation and included the full spectrum of ANCA-associated vasculitis disease severity.
2

METHODS
Study population
The patients were recruited into four randomized therapeutic multicenter trials 
Statistical analysis
Single imputation was done to capture missing values. 17 Continuous variables are expressed as median with 25th and 75th percentiles. Categorical variables are presented as percents and frequencies. Survival was calculated using the Kaplan-Meier method 18 and presented graphically for the whole cohort. The log-rank test was used to compare the overall patient mortality with that of a control cohort matched for age, 
RESULTS
Demography
Five hundred and thirty-five patients with a median (25th -75th percentile) age of 61 (49-69) at diagnosis participated in the trials; 54% of whom were male. of these patients 281 (52%) were diagnosed with Wegener's granulomatosis and 254 (48%) with microscopic polyangiitis. The duration of follow-up ranged from 1 day to 11.46 years, with a median length of follow-up of 5.16 years for all patients and a median of 5.95
years for patients alive at the last visit/end of follow-up. Further demographic data are summarized in Table 2 . 
Survival
Cumulative survival at 1, 2 and 5 years was 88% (95% CI 86-91), 85% (95% CI 82-88) and 78% (95% CI 75-82), respectively. the calculated survival in the matched population was 98%, 97% and 92%, respectively. the overall mortality rate ratio among the patients compared with the controls was 2.6 (95% CI 2.2-3.1) and was significant by log-rank test (p < 0.0001). Although the mortality rate ratio was highest in the first year, it was still significantly elevated for patients with ANCA-associated vasculitis in subsequent years with a ratio of 1.3 (95% CI 1.04-1.65) (Figure 1) . 
Cause of death
there were a total of 133 (25%) deaths during the observation period. the causes of death are summarized in Table 3 . Primary cause: number of patients where specific factor was main factor of death (% of total). Contributing factor: all patients where specific factor contributed to death including primary cause (% of total). CMV, cytomegalovirus infection; PCP, Pneumocystis jiroveci pneumonia.
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Fifty-nine of the 133 deaths (44%) occurred within one year of enrolment. the cause of death differed between patients who died within the first year after enrolment compared with patients who died later ( Table 3 ). In the first year, patients were most likely to die either of infection (48%) or active vasculitis (19%), whereas after one year patients died mostly of cardiovascular disease (26%), malignancy (22%) or infection (20%).
Predictors of death -multivariable analysis
In the multivariable Cox regression the following entry parameters were significant predictors of mortality: advancing age, an estimated glomerular filtration rate of < 15 ml/min, higher Birmingham Vasculitis Activity Score, lower hemoglobin and the time interaction for a higher white blood cell count (Figure 2) . the excess risk of mortality persists after the first year. the main causes of death, infections, cardiovascular causes and malignancies, are similar to the pattern seen in the general population. It is however noteworthy that death due to infection remains very prevalent. So far it is unclear whether there is an excess of cardiovascular and malignant death. It is interesting that, in the current study, most of the excess mortality compared to the general population occurred in the younger age group. This is an important finding which has not been documented before and highlights the importance of comparing patient survival to the general population.
In our cohort increasing age, advanced renal impairment, higher disease activity and low hemoglobin were predictors of mortality. Advanced renal failure and higher age are independent risk factors for therapy-related toxicity, as previously shown by our group. 22 Although current therapy guidelines already make recommendations to modify cyclophosphamide dosing according to age and renal function, 21 further efforts are required to tailor therapy to individual patients taking into account the specific risk from disease manifestations and therapy toxicity. A timely diagnosis might help to prevent irreversible loss of kidney function, but this is hampered by the often silent nature of kidney disease. The identified adverse factors will be useful in the design of new therapeutic studies for risk stratification to address these questions.
Patient survival in our study was comparable to smaller previous studies, which have reported a survival of between 82-97% at one year, 45-91% at five years and 75-88%
at ten years for patients with Wegener's granulomatosis and microscopic polyangiitis. 23 Several previous studies identified advancing age and various markers of impaired kidney function as predictors of early death, 5;24-27 in keeping with our findings.
Disease activity as measured by the Birmingham Vasculitis Activity Score had a small, but statistically significant, effect on survival in the multivariable model. This is in keeping with some previous reports. 28 A low hemoglobin and high white blood cell count imparted an increased risk of death, possibly as markers of the severity of the systemic inflammation. In addition, the importance of neutrophils in particular in the pathogenesis of ANCA-associated vasculitis is well recognized. 29 A possible bias is, however, that patients with more severe disease may have been more likely to have received corticosteroids before enrolment, which would have increased their neutrophil count.
In contrast with several previous studies, 27;30;31 we did not find different survival in patients with either Wegener's granulomatosis or microscopic polyangiitis or patients with different ANCA specificities. The reported differences in previous studies are likely due to either reporting unadjusted mortality without correcting for the older age and more severe renal involvement of patients with microscopic polyangiitis and anti-MPo-ANCA, underpowered multivariable analysis and/or inadequate case mix.
The strengths of this study are that it is to our knowledge the largest study investigating survival in ANCA-associated vasculitis. The patients had a broad range of disease manifestations and were followed up for a median of 6 years for surviving patients.
However, there are some limitations to this study. This cohort was derived from four randomized controlled trials rather than a typical inception cohort. Although the proportions of patients with each severity of ANCA-associated vasculitis (limi- Furthermore, most inception cohorts in ANCA-associated vasculitis are derived from a limited number of centers and geographic areas, while ours covers a large part of Europe further enhancing its generalizability. The ratio between Wegener's granulomatosis and microscopic polyangiitis patients varies geographically; the ratio in our study was typical for ratios found at middle European latitudes. 32 The overall mortality of ANCA-associated vasculitis may have been underestimated as our studies excluded very elderly patients and those with lung hemorrhage at the time of diagnosis. In addition, by necessity patients who died before they could be recruited are also not captured. Patients with only localized disease may be underrepresented as researchers could have been reluctant to enrol them into studies with possible exposure to cytotoxic medication. As such, it is difficult to generalize our results to those specific populations.
Despite recent advances in the therapy of ANCA-associated vasculitis, patients continue to have an excess mortality. this is particularly true for younger patients and patients with severe renal involvement. The increased risk persists after the initial acute presentation. Development of newer treatment strategies has the potential to reduce early deaths due to vasculitis and deaths consequent on the toxicity of current agents.
It is unclear to what extent improved therapies will impact on later mortality.
